WallStSmart

The Cooper Companies, Inc (COO)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 1471% more annual revenue ($66.57B vs $4.24B). COO leads profitability with a 13.5% profit margin vs 4.8%. COO appears more attractively valued with a PEG of 0.52. COO earns a higher WallStSmart Score of 71/100 (B).

COO

Strong Buy

71

out of 100

Grade: B

Growth: 6.7Profit: 5.5Value: 8.0Quality: 6.5
Piotroski: 4/9Altman Z: 2.65

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

COOUndervalued (+60.4%)

Margin of Safety

+60.4%

Fair Value

$209.49

Current Price

$54.12

$155.37 discount

UndervaluedFair: $209.49Overvalued
MRKSignificantly Overvalued (-77.2%)

Margin of Safety

-77.2%

Fair Value

$83.04

Current Price

$150.91

$67.87 premium

UndervaluedFair: $83.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COO4 strengths · Avg: 9.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

EPS GrowthGrowth
357.1%10/10

Earnings expanding 357.1% YoY

PEG RatioValuation
0.528/10

Growing faster than its price suggests

Operating MarginProfitability
20.8%8/10

Strong operational efficiency at 20.8%

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

COO2 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.6%4/10

0.6% revenue growth

Return on EquityProfitability
6.8%3/10

ROE of 6.8% — below average capital efficiency

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.9x4/10

Trading at 8.9x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : COO

The strongest argument for COO centers on Price/Book, EPS Growth, PEG Ratio. PEG of 0.52 suggests the stock is reasonably priced for its growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : COO

The primary concerns for COO are Revenue Growth, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

COO carries more volatility with a beta of 0.82 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

COO scores higher overall (71/100 vs 36/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

The Cooper Companies, Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?